MedTrace Logo

Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

NCT03628131 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2018-09-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of combination chemotherapy with Pazopanib in pediatric patients with relapsed/refractory solid tumor

Conditions

  • Relapsed Pediatric Solid Tumor
  • Refractory Pediatric Solid Tumor

Interventions

DRUG

Pazopanib

Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib

DRUG

Ifosfamide

Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib

DRUG

Carboplatin

Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib

DRUG

Etoposide

Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib

Sponsors & Collaborators

  • Ministry of Health, Republic of Korea

    collaborator OTHER_GOV

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Ki Woong Sung, MD, PhD · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-31
Primary Completion
2023-07-31
Completion
2025-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03628131 on ClinicalTrials.gov